Literature DB >> 19234578

Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: a perspective for emergencies.

Zeynep Tokcaer-Keskin1, A Ruchan Akar, Fatma Ayaloglu-Butun, Ece Terzioglu-Kara, Serkan Durdu, Umit Ozyurda, Mehmet Ugur, Kamil C Akcali.   

Abstract

Mesenchymal stem cells (MSCs) have the capacity to differentiate into osteoblasts, chondrocytes, adipocytes, myocytes, and cardiomyocytes. Several established methods are presently available for in vitro isolation of MSCs from bone marrow. However, the duration necessary to culture them can be a major handicap to cell-based therapies needed for such urgent cardiovascular conditions as acute myocardial infarction and acute hindlimb ischemia. The best timing of cardiomyocyte differentiation induction after MCS isolation and expansion is still an unresolved issue. Our goal was to investigate the possibility of obtaining functional cardiomyocytes from rat MSC within a shorter time period. We examined MSCs' colony-forming capacity, CD90 and CD34 immunoreactivity during the 14 days of culturing. Cardiomyocyte differentiation was induced by 5-azacytidine. Immunohistochemic staining, together with intracellular Ca2+ measurement experiments, revealed that MSCs do not differentiate into any specific cell lineage but show the characteristics of MSCs on both the 9th and 14th days of the culture. To check the potential for differentiation into cardiomyocytes, experiments with caffeine application and depolarization with KCl were performed. The cells possessed some of the specific biochemical features of contracting cells, with slightly higher capacities on the 14th day. Cells from 9th and 14th days of the culture that were treated with 5-azacytidine had a higher expression of cardiac-specific markers such as troponin I, alpha-sarcomeric actin, and MEF2D compared with the control groups. This study illustrates that it is possible to get functional cardiomyocytes from in vitro MSC culture in a shorter time period than previously achieved. This reduction in time may provide emergency cases with access to cell-based therapies that may have previously been unavailable.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234578     DOI: 10.1139/Y08-111

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  14 in total

1.  Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study.

Authors:  Remco Koninckx; Annick Daniëls; Severina Windmolders; Françoise Carlotti; Urbain Mees; Paul Steels; Jean-Luc Rummens; Marc Hendrikx; Karen Hensen
Journal:  Cell Mol Life Sci       Date:  2010-10-24       Impact factor: 9.261

2.  Therapeutic potential effect of bone marrow-derived mesenchymal stem cells on chronic liver disease in murine Schistosomiasis Mansoni.

Authors:  Mohamed H Hegab; Somia H Abd-Allah; Maha S Badawey; Ayman A Saleh; Ashraf S Metwally; Ghada M Fathy; Soad M Nada; Sara A Abdel-Rahman; Amira A Saleh; Amal Fawzy; Mohammed Abu El-Magd
Journal:  J Parasit Dis       Date:  2018-04-23

Review 3.  Mesenchymal stem cells at the intersection of cell and gene therapy.

Authors:  Timothy J Myers; Froilan Granero-Molto; Lara Longobardi; Tieshi Li; Yun Yan; Anna Spagnoli
Journal:  Expert Opin Biol Ther       Date:  2010-12       Impact factor: 4.388

4.  Characterisation and immunosuppressive activity of human cartilage-derived mesenchymal stem cells.

Authors:  Pratheep Sandrasaigaran; Satar Jabbar Rahi Algraittee; Azfar Rizal Ahmad; Sharmili Vidyadaran; Rajesh Ramasamy
Journal:  Cytotechnology       Date:  2018-03-01       Impact factor: 2.058

5.  The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6.

Authors:  Zeynep Tokcaer-Keskin; Zeliha G Dikmen; Fatma Ayaloglu-Butun; Sinan Gultekin; Sergei M Gryaznov; Kamil Can Akcali
Journal:  Stem Cell Rev Rep       Date:  2010-06       Impact factor: 5.739

6.  The effect of estrogen on bone marrow-derived rat mesenchymal stem cell maintenance: inhibiting apoptosis through the expression of Bcl-xL and Bcl-2.

Authors:  Fatma Ayaloglu-Butun; Ece Terzioglu-Kara; Zeynep Tokcaer-Keskin; Kamil Can Akcali
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

7.  S100A16 inhibits osteogenesis but stimulates adipogenesis.

Authors:  Dong Li; Rihua Zhang; Weidong Zhu; Yi Xue; Yuanyuan Zhang; Qiong Huang; Menglan Liu; Yun Liu
Journal:  Mol Biol Rep       Date:  2013-03-25       Impact factor: 2.316

8.  Delayed enrichment of mesenchymal cells promotes cardiac lineage and calcium transient development.

Authors:  Liliana Grajales; Jesús García; Kathrin Banach; David L Geenen
Journal:  J Mol Cell Cardiol       Date:  2010-01-06       Impact factor: 5.000

9.  Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment.

Authors:  Stephan Fricke; Manuela Ackermann; Alexandra Stolzing; Christoph Schimmelpfennig; Nadja Hilger; Jutta Jahns; Guido Hildebrandt; Frank Emmrich; Peter Ruschpler; Claudia Pösel; Manja Kamprad; Ulrich Sack
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

Review 10.  Mesenchymal stromal cells: current understanding and clinical status.

Authors:  Husein K Salem; Chris Thiemermann
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.